Track topics on Twitter Track topics that are important to you
Gossamer Bio, led by former Receptos CEO Faheem Hasnain and CMO Sheila Gujrathi, revealed $100m in seed and Series A...
Having co-led the $100 million Series A transaction in Gossamer Bio, the founder of Omega Funds believes its time for the fund to come out of its protective shell.
Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need.
Co-founded by Faheem Hasnain and Sheila Gujrathi, M.D., former executive leadership of Receptos, Inc. Omega Funds founding seed investor ...
With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking...
The Danish CNS specialist has entered into a pact with Vanderbilt University to jointly develop a new way to treat...
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various ta...
We have published hundreds of Gossamer Bio, Inc. news stories on BioPortfolio along with dozens of Gossamer Bio, Inc. Clinical Trials and PubMed Articles about Gossamer Bio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Gossamer Bio, Inc. Companies in our database. You can also find out about relevant Gossamer Bio, Inc. Drugs and Medications on this site too.
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...